GALAPAGOS NV-SPON ADR (GLPG)

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,338 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Company Info

GALAPAGOS NV-SPON ADR

Generaal De Wittelaan L11 A3

MALINES (MECHELEN) ANTWERPEN 2800

P: 3215342900

CEO: Onnovan deStolpe

Employees: 1338

Website: https://www.glpg.com/